1.
|
Sterzel RB, Schulze-Lohoff E and Marx M:
Cytokines and mesangial cells. Kidney Int Suppl. 39:S26–S31.
1993.PubMed/NCBI
|
2.
|
Ruef C, Budde K, Lacy J, et al:
Interleukin 6 is an autocrine growth factor for mesangial cells.
Kidney Int. 38:249–257. 1990. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Horii Y, Muraguchi A, Iwano M, et al:
Involvement of IL-6 in mesangial proliferative glomerulonephritis.
J Immunol. 143:3949–3955. 1989.PubMed/NCBI
|
4.
|
Fukatsu A, Matsuo S, Tamai H, Sakamoto N,
Matsuda T and Hirano T: Distribution of interleukin-6 in normal and
diseased human kidney. Lab Invest. 65:61–66. 1991.PubMed/NCBI
|
5.
|
Bergstein J, Leiser J and Andreoli S: The
clinical significance of asymptomatic gross and microscopic
hematuria in children. Arch Pediatr Adolesc Med. 159:353–355. 2005.
View Article : Google Scholar : PubMed/NCBI
|
6.
|
Abbott F, Ryan JJ, Ceska M, Matsushima K,
Sarraf CE and Rees AJ: Interleukin-1 beta stimulates human
mesangial cells to synthesize and release interleukins-6 and -8.
Kidney Int. 40:597–605. 1991.PubMed/NCBI
|
7.
|
Stenvinkel P, Ketteler M, Johnson RJ, et
al: IL-10, IL-6, and TNF-α: central factors in the altered cytokine
network of uremia - the good, the bad, and the ugly. Kidney Int.
67:1216–1233. 2005.
|
8.
|
Ranieri E, Gesualdo L, Petrarulo F and
Schena FP: Urinary IL-6/EGF ratio: a useful prognostic marker for
the progression of renal damage in IgA nephropathy. Kidney Int.
50:1990–2001. 1996. View Article : Google Scholar
|
9.
|
Safian RD and Textor SC: Renal-artery
stenosis. N Engl J Med. 344:431–442. 2001. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Donadio JV, Bergstralh EJ, Offord KP,
Holley KE and Spencer DC; Mayo Nephrology Collaborative Group:
Clinical and histopathologic associations with impaired renal
function in IgA nephropathy. Clin Nephrol. 41:65–71.
1994.PubMed/NCBI
|
11.
|
Alamarline E, Sabatier JC and Berthoux FC:
Comparison of pathological lesions on repeated biopsies in 73
patients with primary IgA glomerulonephritis: value of quantitative
scoring and approach to final prognosis. Clin Nephrol. 34:45–51.
1990.PubMed/NCBI
|
12.
|
Okada H, Suzuki H, Konishi K, Sakaguchi H
and Saruta T: Histological alterations in renal specimens as
indicators of prognosis of IgA nephropathy. Clin Nephrol.
37:235–238. 1992.PubMed/NCBI
|
13.
|
Leehey DJ, Singh AK, Alavi N and Singh R:
Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl.
77:S93–S98. 2000. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Ruilope LM, Malacco E, Khder Y, Kandra A,
Bönner G and Heintz D: Efficacy and tolerability of combination
therapy with valsartan plus hydrochlorothiazide compared with
amlodipine monotherapy in hypertensive patients with other
cardiovascular risk factors: the VAST study. Clin Ther. 27:578–587.
2005. View Article : Google Scholar
|
15.
|
Ruiz-Ortega M, Esteban V, Rupérez M, et
al: Renal and vascular hypertension-induced inflammation: role of
angiotensin II. Curr Opin Nephrol Hypertens. 15:159–166. 2006.
View Article : Google Scholar : PubMed/NCBI
|
16.
|
Mehta PK and Griendling KK: Angiotensin II
cell signaling: physiological and pathological effects in the
cardiovascular system. Am J Physiol Cell Physiol. 292:C82–C97.
2007. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Schwartz N, Michaelson JS and Putterman C:
Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for
lupusnephritis. Ann N Y Acad Sci. 1109:265–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
18.
|
Ritz E and Stefanski A: Diabetic
nephropathy in type II diabetes. Am J Kidney Dis. 27:167–194. 1996.
View Article : Google Scholar
|
19.
|
Dalla Vestra M, Mussap M, Gallina P, et
al: Acute-phase markers of inflammation and glomerular structure in
patients with type 2 diabetes. J Am Soc Nephrol. 16(Suppl 1):
S78–S82. 2005.PubMed/NCBI
|
20.
|
Epstein M and Campese VM: Pleiotropic
effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors on renal function. Am J Kidney Dis. 45:2–14. 2005.
View Article : Google Scholar : PubMed/NCBI
|
21.
|
Shah S, Paparello J and Danesh FR: Effects
of statin therapy on the progression of chronic kidney disease. Adv
Chronic Kidney Dis. 12:187–195. 2005. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Coleman DL and Ruef C: Interleukin-6: an
autocrine regulator of mesangial cell growth. Kidney Int.
41:604–606. 1992. View Article : Google Scholar : PubMed/NCBI
|